ATLANTA, June 27, 2024  — VERO Biotech Inc, a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the expansion of its commercial team to better address the needs of its current acute care hospital customers and become the leading provider of inhaled nitric oxide solutions. The expansion includes the addition of Suzanne Hagin as VP of Commercial Operations & Marketing and Rebecca Van Doren as VP of Strategic Development.  Mrs. Hagin and Mrs. Van Doren are both seasoned biotech professionals with significant commercial and strategic leadership experience in the drug-device markets, specifically in nitric oxide.

Suzanne Hagin joins VERO with 20 years of leadership experience, spearheading marketing strategy and product launches for diagnostics, medical device, and pharmaceutical organizations. Over the last 6 years, Suzanne led the commercial development of a nitric oxide drug-device solution while serving as General Manager for Airgas Therapeutics. We welcome Suzanne as the new VP of Commercial Operations & Marketing as she takes on the role of leading VERO’s Commercial Operations.

Rebecca Van Doren joins VERO with 20 years of extensive executive-level leadership experience within the pharmaceutical, medical device, and device-drug industries in both the US and Global markets.  Rebecca has over 10 years of experience in the nitric oxide market where she previously served as the Head of US Sales with Beyond Air and National Director of Sales, Marketing & General Manager for Mallinckrodt in both the US and Australian markets.  We welcome Rebecca as the new VP of Strategic Development, as she takes on the role of developing and executing VERO’s Commercial Strategy.

About GENOSYL^®

Indication

GENOSYL (nitric oxide) gas, for inhalation, is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Important Safety Information

• GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
• Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
• Methemoglobin levels in the blood increase with the dose of nitric oxide; following discontinuation or reduction of nitric oxide, methemoglobin levels return to baseline over a period of hours.
• Methemoglobin, NO₂, and PaO₂ should be monitored during nitric oxide administration.
• In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema.
• The most common adverse reaction is hypotension.
• Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
• GENOSYL must be administered using a calibrated GENOSYL Delivery System. Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.

Please visit www.vero-biotech.com for the full Prescribing Information for GENOSYL.

About GENOSYL^® DS

GENOSYL DS is VERO Biotech’s lead product. This proprietary delivery system eliminates the need for large nitric oxide tanks and the associated logistical burden.  GENOSYL DS is a tankless and portable system engineered with redundant backup features, which delivers a constant concentration of inhaled nitric oxide gas to patients with an easy-to-use interface and portability features.

About VERO Biotech

VERO Biotech Inc. (formerly known as GeNO LLC) is focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases.

VERO Biotech is dedicated to improving the lives of patients by leading the development of innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever inhaled nitric oxide treatment is needed.

Forward Looking Statements

This press release and any statements of representatives of VERO Biotech Inc. related thereto that are not historical in nature contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, without limitation, statements with respect to VERO Biotech’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “seeks,” “intends,” “plans,” “potential” or similar expressions, including statements with respect to the potential effects of its products and plans to assess and undertake next steps for VERO Biotech Inc.  These statements are based upon the current beliefs and expectations of VERO Biotech’s management and are subject to significant risks and uncertainties. Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various risk factors (many of which are beyond VERO Biotech’s control).

For information, please visit www.vero-biotech.com or contact Ziad Mohamed at contactus@vero-biotech.com.

SOURCE VERO Biotech Inc.